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Monohexosylceramides (CMHs, or cerebrosides) have been reported as membrane and cell wall constituents
of both pathogenic and nonpathogenic fungi, presenting remarkable differences in their ceramide moiety
compared to mammalian CMHs. Current evidence suggests that CMHs are involved in fungal differentiation
and growth and contribute to host immune response. Here we describe a structural diversity between cere-
brosides obtained from different forms of the human pathogen Fonsecaea pedrosoi. The major CMH species
produced by conidial forms displayed the same structure previously demonstrated by our group for mycelia,
an N-2-hydroxyhexadecanoyl-1--D-glucopyranosyl-9-methyl-4,8-sphingadienine. However, the major cerebro-
side species purified from sclerotic cells carries an additional hydroxyl group, bound to its long-chain base. The
structural difference between cerebrosides from mycelial and sclerotic cells was apparently not relevant for
their antigenicity, since they were both recognized at similar levels by sera from individuals with chromoblas-
tomycosis and a monoclonal antibody to a conserved cerebroside structure. Preincubation of fungal cells with
anti-CMH monoclonal antibodies had no effect on the interaction of F. pedrosoi sclerotic cells with murine
macrophages. In contrast to what has been described for other fungal species, sclerotic bodies are resistant to
the antifungal action of anti-CMH antibodies. Immunofluorescence analysis showed that recognition of
sclerotic cells by these antibodies only occurs at cell wall regions in which melanization is not evident.
Accordingly, melanin removal with alkali results in an increased reaction of fungal cells with anti-CMH
antibodies. Our results indicate that cerebroside expression in F. pedrosoi cells is associated with dimorphism
and melanin assembly on the fungal cell wall.
The dematiaceous fungus Fonsecaea pedrosoi is the principal
etiologic agent of chromoblastomycosis, a chronic and granu-
lomatous mycosis usually confined to skin and subcutaneous
tissues (15). Predominant in tropical and subtropical areas, this
disease is normally described in arms and legs of labor workers,
which are constantly in contact with soil, where F. pedrosoi
grows as a saprophyte (5). Characterized by dry, crusted, warty,
and violaceous lesions, chromoblastomycosis has a compli-
cated treatment. It includes a combination of antifungal drugs
and surgical excision; however, incorrect diagnosis, relapses,
and therapy interruption are frequent, causing an elevated
percentage of morbidity (5). Cryotherapy and laser surgery are
alternative options for removing the lesions (6).
Although fungal infection occurs after traumatic inoculation
of mycelium fragments and conidial forms, excised chromo-
blastomycosis lesions reveal mostly sclerotic bodies and a small
number of mycelium fragments (5, 6, 10). The morphological
changes from conidial forms to sclerotic bodies occur inside
the host, associated with an intense granulomatous response
(11, 27). Interestingly, sclerotic cells display a unique shape
along with a muriform arrangement within the tissue, which
impairs an efficient host cell attack and antifungal drug access
(10).
Initially described as mammalian cell membrane building
blocks (14), monohexosylceramides (CMH) have been demon-
strated to be involved in relevant cellular functions (4, 14).
Several studies have shown CMH and more complex glyco-
sphingolipids (GSL) as antigens (4), mediators of cell adhesion
(14), and key molecules in signal transduction upon cell-cell
interaction (14). Special attention has been given to fungal
CMH in the last two decades. All fungal species studied so far
were able to synthesize CMH, with Saccharomyces cerevisiae
being the unique exception (4). Comparing CMH from several
pathogenic fungi, a very conservative structure has been ob-
served, consisting of a ceramide moiety containing 9-methyl-
4,8-sphingadienine in amidic linkage to 2-hydroxyoctadecanoic
or 2-hydroxyhexadecanoic acids and glucose or galactose as the
carbohydrate portion (4).
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Antigenic properties have also been described for fungal
CMH. Rodrigues and colleagues (24) purified human antibod-
ies against CMH from sera of patients with cryptococcosis.
These antibodies reacted with the cell wall and reduced cell
budding and growth of Cryptococcus neoformans. Moreover,
sera from patients with histoplasmosis, aspergillosis, and para-
coccidioidomycosis reacted with C. neoformans CMH (24). An-
tibodies to CMH also inhibited cell differentiation of Colleto-
trichum gloeosporioides (9), Pseudallescheria boydii (23), and
Candida albicans (24). We recently tested the activity of a
monoclonal anti-CMH antibody against conidial forms of F.
pedrosoi (22) and detected a direct fungicidal action. Preincu-
bation of conidial cells with anti-CMH also increased the mu-
rine peritoneal macrophage capacity to engulf and kill the
fungus. CMH were also identified as specific targets for the
antifungal plant defensin RsAFP2 (30). Together, these data
confirmed that these GSL are not only antigenic molecules but
also targets for the action of antifungal compounds.
Here, we purified and characterized CMH from sclerotic,
mycelial, and conidial forms of F. pedrosoi cultured in a defined
medium. The major CMH of mycelial and conidial forms
present the same structure, an N-2-hydroxyhexadecanoyl-1--
D-glucopyranosyl-9-methyl-4,8-sphingadienine, described pre-
viously for mycelial forms cultured in complex medium (22).
However, sclerotic bodies synthesize a unique cerebroside spe-
cies, containing a 9-methyl-4,8-sphingadienine carrying an ex-
tra hydroxyl group. Such difference suggests the association
between F. pedrosoi CMH and its dimorphism process. Al-
though structurally different, these molecules react against sera
from patients with chromoblastomycosis and a monoclonal
antibody to a conserved cerebroside in equivalent levels, as
determined by enzyme-linked immunosorbent assay (ELISA).
The monoclonal antibody to CMH neither killed sclerotic cells
nor influenced their adhesion by murine macrophages, in con-
trast to a previous description for conidia (22). Finally, we
observed by immunofluorescence assays that melanin expres-
sion at the cell wall of F. pedrosoi interferes with recognition of
CMH, which may explain the resistance of sclerotic forms to
anticerebroside antibodies.
MATERIALS AND METHODS
Microorganism and growth conditions. F. pedrosoi strain VLP was isolated
from a human case of chromoblastomycosis (1). Stock cultures were maintained
on Sabouraud dextrose agar under mineral oil and kept at 4°C. Transfers were
made at 6-month intervals. Mycelial and sclerotic bodies were obtained from
inoculation in Butterfield’s chemically defined medium (7) and cultured for 30
days at room temperature at pH 6.5 and 2.7; respectively. Conidial forms were
obtained under constant agitation with a stirring bar for 5 days in the same
medium, pH 5.5, and at room temperature. Conidial, mycelial, and sclerotic cells
were collected by filtration and washed 3 times in 0.01 M phosphate-buffered
saline (PBS), pH 7.2, before all of the experiments. For interactions with mac-
rophages and immunofluorescence assays, sclerotic cells were strongly vortexed
to disrupt aggregated cells, followed by centrifugation (200  g) for 1 min to
pellet the enduring aggregated forms, leaving the disaggregated cells in solution.
Lipid extraction and purification of CMH. GSL from different forms of F.
pedrosoi were extracted at room temperature successively with mixtures of chlo-
roform-methanol (2:1, 1:1, and 1:2 [vol/vol]). The extracts were pooled and dried
under vacuum (crude lipid). The crude lipid extract was partitioned according to
the method of Folch et al. (12). The lipids recovered from Folch’s lower phase
were fractionated on a silica gel column by elution with chloroform, acetone, and
then methanol. The enriched glycolipid fraction was then purified by another
silica gel column chromatography. This column was eluted sequentially with
different mixtures of chloroform-methanol (95:5, 9:1, 8:2, and 1:1 [vol/vol]) and,
finally, with methanol. Samples were analyzed on high-performance thin-layer
chromatography (HPTLC) plates developed with chloroform-methanol-water
(65:25:4 [vol/vol/vol]). The spots were visualized with iodine vapor and by char-
ring with orcinol-H2SO4 (26). Quantification of GSL was made by using the
Scion Image software (Scion Corporation, NIH), with glucose as the colorimetric
standard.
ESI-MS analysis. Glycolipids were analyzed by electrospray ionization-mass
spectrometry (ESI-MS) using a Finnigan LCQ-Duo ion trap instrument (Thermo
Electron, San Jose, CA). Samples were diluted in chloroform-methanol (1:1,
[vol/vol]), containing 10 mM lithium iodide, and introduced into ESI-MS at a 5-
to 10-l/min flow rate, with the assistance of an infusion micropump (Harvard
Apparatus, Cambridge, MA). Analyses were carried out in the positive (ESI)
mode. The source and capillary voltages were 4.5 kV and 3 V, respectively
(ESI). The capillary temperature was kept at 200°C. Spectra were collected at
a 200- to 2,000-m/z range. Source-induced dissociation was obtained at 25 V. Ion
trap collision-induced dissociation (ESI-MS/MS or ESI-MSn) experiments were
carried out at 20 to 60% (1 to 3 eV) normalized relative collision energy. All
spectra were processed using the Xcalibur software (Thermo Electron).
CMH permethylation. The purified fraction containing GlcCer from sclerotic
bodies of F. pedrosoi was permethylated essentially according to the method of
Ciucanu and Kerek (8). Briefly, a few milligrams of NaOH powder was added to
the completely dried sample placed on borosilicate tubes. Then, 30 l of an
iodomethane-dimethyl sulfoxide (1:1 [vol/vol]) mixture was added and the tube
sealed. After sonication for 2 to 3 min, the samples were incubated at room
temperature for 1 h with a quick agitation every 15 min. The reaction was
stopped by the addition of 15% acetic acid in methanol (200 l), and 100 l of
water and 300 l of chloroform were added. After a 15-minute centrifugation at
2,000  g, the aqueous phase was discarded and the organic phase washed 4 to
5 times with water. After evaporation of chloroform under a nitrogen stream, the
samples were analyzed as described above.
Carbohydrate compositional analysis. GSL were hydrolyzed with 3 M triflu-
oroacetic acid at 100°C for 3 h, and the resulting monosaccharides were identi-
fied by HPTLC and gas chromatography as their alditol-acetate derivatives (25)
using an OV-225 fused silica capillary column (30 m by 0.25 mm, internal
diameter), with the temperature programmed from 50 to 220°C at 5°C/min.
Glucose and galactose (Sigma-Aldrich) were used as standards.
Reactivity of purified CMH with antibodies to cerebrosides. Ninety-six-well
microplates were washed with n-butanol and ethanol and then dried at room
temperature (29). Purified CMH from mycelial and sclerotic cells were dissolved
in a chloroform-methanol (2:1 [vol/vol]) mixture to form a 4 M solution. This
preparation was diluted in a mixture of ethanol-methanol (1:1, vol/vol) to a final
concentration of 0.04 M. Fifty microliters (2 nmol) of this solution was added
to each well of a solvent-washed 96-well plate and evaporated to dryness at room
temperature. After blocking with Tris-buffered saline (TBS) supplemented with
bovine serum albumin (3 mg/ml) overnight at 4°C, the wells were washed with
TBS and incubated (1 h, room temperature) with serially diluted sera from
chromoblastomycosis patients. Sera from 17 individuals infected with F. pedrosoi
presenting typical lesions of chromoblastomycosis were pooled and used in this
study. Sera from healthy individuals with no previous laboratory exposure to F.
pedrosoi were also collected and tested against the same preparation by ELISA.
Alternatively, a monoclonal anti-CMH antibody (12 g/ml, starting dilution) was
used as a probe to detect CMH (9, 22). After washing in TBS, an alkaline
phosphatase-labeled goat anti-mouse or anti-human immunoglobulin was added
(1:5,000), followed by incubation for 1 h at room temperature. The plate was
subsequently washed three times with TBS and once with assay buffer (0.1 M
glycine buffer containing 1 mM MgCl2, 1 mM ZnCl2, pH 10.4). Reactions were
visualized by the addition of assay buffer containing 1 mg/ml of p-phenyl phos-
phate, followed by determination of absorbance (405 nm) in a microplate reader
spectrophotometer.
Effects of antibodies to CMH on cell growth. F. pedrosoi sclerotic cells (2 
102) were suspended in 100 l of PBS supplemented with antibodies to CMH in
concentrations varying to 1.5 to 100 g/ml. In this range of concentrations,
antibodies to CMH were demonstrated to be inhibitory for different fungal
species (9, 21–23). Cell suspensions were then incubated in the presence of
antibodies to CMH for 8 h at 28°C. Viable CFU were evaluated by plating 100
l of the samples onto Sabouraud dextrose agar plates, followed by incubation
for 10 days at room temperature. Control systems were similarly treated with an
irrelevant immunoglobulin (mouse immunoglobulin G2b [IgG2b] to human
laminin).
Interaction of sclerotic cells with J774.16 macrophages. The murine macro-
phage cell line J774.16 was cultured in Dulbecco’s minimal essential medium
(Gibco-BRL, Gaithersburg, MD) supplemented with 2 mM L-glutamine and
10% complement-inactivated fetal bovine serum (Gibco-BRL, Gaithersburg,
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MD). Cells were harvested with trypsin-EDTA and washed twice with Dulbec-
co’s minimal essential medium. Cell viability was checked by trypan blue staining.
The cells were allowed to adhere onto coverslips placed in 24-well culture plates
(5  105 per well) or into the wells of a 96-well plate (105 per well). After 30 min
at 37°C in a 5% CO2 atmosphere, nonadherent cells were then removed. Ad-
hered macrophages were washed twice with culture medium and then cultured
for 24 h. Sclerotic cells of F. pedrosoi were treated with anti-CMH monoclonal
antibody (10 g/ml), PBS, or an irrelevant IgG (10 g/ml) for 1 h before
interaction with macrophages. Fungal cells were washed in PBS and allowed to
interact with macrophages at fungi/macrophage ratios of 1:1 or 1:10 for 1 h at
37°C. The proportion of sclerotic cells per phagocyte was established based on
the property that these forms of F. pedrosoi are much larger than other fungal
cells. After removal of nonadherent fungi by washing, the coverslips were fixed
with methanol and stained with Giemsa. In each system, 1,000 macrophages were
counted and the results expressed as the number of adhered fungi per 100
macrophages. Control experiments with conidial cells were performed at a fungi/
macrophage ratio of 1:10, and the adhesion index was at least 3 times higher than
that for sclerotic cells (data not shown). These experiments were repeated 3
times with similar results.
Killing assays were performed in 96-well plates. After 1 h of incubation, the
wells were washed three times with PBS and macrophages were lysed with sterile
cold water. The resulting suspension was plated onto brain heart infusion agar
plates. After 10 days, the number of CFU was determined. All experiments were
performed in triplicate sets and statistically analyzed by using Student’s t test.
Partial depletion of melanin in F. pedrosoi cells (2). A pellet of 108 cells
(conidia) or 10 mg (mycelia) was resuspended in 1 ml of 0.5 M NaOH and
incubated overnight at 25°C and under constant agitation. Sclerotic cells (10 mg)
that are more melanized (3) and more resistant to alkali extraction were sus-
pended in 2 M NaOH (1 ml, final volume) and then strongly vortexed for 30 s.
This suspension was slightly homogenized with a Dounce homogenizer (3
strokes) and then incubated as described for mycelia and conidia. Cell suspen-
sions were then washed exhaustively with PBS and fixed in 4% paraformalde-
hyde. Melanin removal was evaluated visually or by immunofluorescence analysis
with antibodies to melanin, as described below.
Immunofluorescence analysis. The antibodies used in this study consisted of a
monoclonal antibody to conserved CMH, produced and characterized in previ-
ous studies (9, 22), and a polyclonal preparation of antimelanin antibodies,
obtained from sera of human individuals with chromoblastomycosis. Human
antibodies to melanin were purified as previously described by our group (3)
using sera described above (see “Reactivity of purified CMH with antibodies to
cerebrosides”). Control or alkali-treated cells of F. pedrosoi were fixed in 4%
paraformaldehyde cacodylate buffer (0.1 M, pH 7.2) for 1 h at room temperature.
Fixed cells were washed twice in PBS and incubated in the same buffer contain-
ing 1% bovine serum albumin for 1 h. Cells were washed in PBS and sequentially
incubated with antibodies to CMH (at 10 g/ml) and a fluorescein isothiocya-
nate-labeled anti-mouse IgG (at 1:100 dilution) for 1 h at room temperature. The
cells were washed again and then incubated with human antibodies to melanin at
10 g/ml. After washing, fungal preparations were incubated with a Texas Red-
labeled anti-human IgG at a 1:100 dilution. Control systems consisting of fungal
cells incubated only with secondary antibodies were also prepared. Alkali-treated
and untreated cells were finally washed and microscopically observed with an
Axioplan 2 (Zeiss, Germany) fluorescence microscope. Images were acquired
using a Color View SX digital camera and processed with the software system
analySIS (Soft Image System).
RESULTS
Lipid extraction and CMH purification. Crude lipid extrac-
tion and CMH purification were carried out as previously de-
scribed (4). Identical strategies of CMH purification were used
for all different forms of F. pedrosoi (Fig. 1A). After Folch’s
partition (12), CMH present at the lower phase was partially
purified using a Silica Gel 60 chromatography column. Accord-
ing to HPTLC analysis, the fraction eluted with acetone was
enriched in CMH (data not shown). This fraction was dried,
resuspended in CHCl3, and then reapplied to another silica gel
column. In all cases, the fraction containing purified CMH was
eluted with chloroform-methanol (9:1 [vol/vol]) (data not
shown). The HPTLC analysis of purified CMH from all differ-
ent forms of F. pedrosoi revealed a retention factor (Rf) (Fig.
1B) identical to that obtained for a previously characterized
CMH purified from F. pedrosoi mycelia cultivated in Kauff-
man’s medium (22).
Structural analysis of CMH from F. pedrosoi. Purified CMH
from different stages of F. pedrosoi were analyzed by positive
ion mode ESI-MS. Scanning from 700 to 800 m/z of purified
CMH samples revealed a profile similar to what has been
described for other fungal cerebrosides (4). Abundant mono-
lithiated peaks between m/z 730 and 760 were observed (Fig.
2). CMH purified from mycelia presented a major species at
m/z 734 [M  Li] (Fig. 2A), while two major ion species
were observed at m/z 734 [M  Li] and 750 [M  Li] for
sclerotic cell CMH (Fig. 2B). Conidial forms also presented
both species; however, the intensity of the peak at m/z 750 was
relatively low (Fig. 2C). The molecular species corresponding
to these major peaks were submitted to ESI-MS/MS analysis
(Fig. 3). The fragmentation profile was identical for the paren-
tal ions with m/z values corresponding to 734, which repre-
sented the major peak obtained for purified molecules from
mycelia and conidia (Fig. 2A and C). The loss of 162 units,
common to all CMH analyzed and diagnostic of a monosac-
charide unit, gave rise to daughter ions at m/z 572 and 588 [M
 Hexose  Li] corresponding to the ceramide monolithi-
ated ion from the parental ions at m/z 734 and 750, respec-
tively. The daughter ions at m/z 480, observed in CMH of all
three stages of F. pedrosoi, and m/z 496 observed in conidial
and sclerotic cell CMH are consistent with a loss of an OH C16
fatty acid. The difference of 16 units observed among the
conidial and sclerotic bodies’ CMH parental ions (Fig. 2A and
B) remained detectable after loss of either monosaccharide or
fatty acid, suggesting that the long chain base could possibly
present an extra hydroxyl group. This hypothesis was strongly
supported after the analysis of the permethylated CMH deriv-
ative showing a molecular and monolithiated ion at m/z 862,
consistent with an addition of 8 methyl group units (Fig. 3,
inset). Fragmentation of permethylated CMH from a sclerotic
body suggests that the additional hydroxyl group is linked to
C-4 or -5 of its long chain base (data not shown). In all CMH
FIG. 1. Purification of CMH from different F. pedrosoi forms. A
summary of the purification strategy is shown in panel A. C, chloro-
form; M, methanol. Purified samples from mycelia (a), conidia (b),
sclerotic cells (c), and a CMH standard (d) were analyzed by HPTLC
and are shown in panel B.
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studied in this work, the sugar portion was defined as glucose
after HPTLC and gas chromatography analysis (data not
shown). According to these data, the CMH purified from my-
celia of F. pedrosoi cultivated in defined medium is identical to
the one synthesized by mycelia grown in Kauffman’s medium
(22), consisting of 9-methyl-4,8-sphingadienine in amidic link-
age to 2-hydroxyhexadecanoic acid. The same structure was
assigned as the principal CMH from conidial cells. On the
other hand, the major CMH synthesized by sclerotic cells bears
an extra hydroxyl group in its long chain base (trihydroxyl-
sphingadienine), which is also produced in minor amounts in
conidial forms (Fig. 4).
F. pedrosoi CMH are similarly recognized by anticerebroside
antibodies. Anti-CMH antibodies have been detected in pa-
tients with different mycoses, such as aspergillosis, cryptococ-
cosis, histoplasmosis, and paracoccidioidomycosis (24). Based
on this information, we evaluated the production of antibodies
to cerebrosides during the human infection by F. pedrosoi (Fig.
5A). Our data reveal that anti-CMH antibodies are in fact
produced during chromoblastomycosis, and the serological re-
activity is similar when cerebrosides from mycelial or sclerotic
forms are used. Similar results were obtained when a mono-
clonal antibody to conserved fungal CMH was used. According
to the results shown in Fig. 5B, the monoclonal antibody reacts
well with both CMH, although the affinity level for the cere-
broside extracted from sclerotic cells seems to be less than that
observed for the mycelial glycolipid.
Anti-CMH antibodies have no direct effect on sclerotic cells.
Considering that anti-CMH monoclonal antibodies are able to
kill conidia of F. pedrosoi (22) and yeast cells of C. neoformans
(24) and inhibit fungal differentiation of C. albicans, C. gloes-
porioides, and P. boydii (9, 23, 24), we decided to test the direct
effect of monoclonal anti-CMH antibodies on sclerotic cell
viability and cell differentiation. We concluded that, even after
incubation of higher concentrations of anti-CMH antibodies
(100 g/ml) with sclerotic cells, there was no difference in the
ability to grow or differentiate between control and antibody-
treated cells (data not shown). Therefore, although sclerotic
cells produce antigenic CMH (Fig. 5), they seem to be espe-
cially resistant to the direct effect of anti-CMH antibodies.
Association of sclerotic cells with murine macrophages in
the presence of anti-CMH. Antibodies to CMH are opsonic in
FIG. 2. ESI-MS spectra of the intact CMH purified from mycelial
(A), sclerotic (B), and conidial (C) forms of F. pedrosoi.
FIG. 3. ESI-MS/MS spectra showing the analysis of lithiated frag-
ments derived from CMH molecular ions from F. pedrosoi mycelia (A),
sclerotic bodies (B), and conidia (C). CMH from sclerotic cells were
permethylated, and the corresponding molecular ion, derived from the
peak at m/z 750, is shown in the inset in panel B.
FIG. 4. Representation of native (top) and permethylated (bot-
tom) CMH (m/z 750) from sclerotic cells. The binding site of the
additional hydroxyl group, undefined in underivatized samples, in-
volves C-4 or -5 in the fatty acid moiety of CMH.
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a model of phagocytosis involving F. pedrosoi conidia and
mouse peritoneal macrophages (22). We therefore investi-
gated the influence of the monoclonal antibody to CMH on the
adhesion and killing of sclerotic cells by the murine macro-
phage cell line J774.16. For this purpose, we incubated scle-
rotic bodies, previously treated with irrelevant IgG or anti-
CMH antibodies (10 g/ml), for 1 h with a monolayer of
murine macrophages in ratios of 1 fungus per macrophage or
10 phagocytes per fungal cell. The results shown in Fig. 6A
suggest that preincubation of sclerotic bodies with the antibody
did not enhance fungal association to macrophages in a signif-
icant way (n  1,000 macrophages, P  0.05), although a small
tendency of higher adhesion of antibody-treated sclerotic cells
was observed. Results are shown for experiments using the
10:1 fungus/phagocyte ratio, but similar profiles were obtained
when fungal cells and phagocytes were incubated in equivalent
amounts (data not shown).
Pretreatment of sclerotic cells with anti-CMH antibodies did
not influence the killing capacity of macrophages (Fig. 6B).
Such results demonstrated that although antibodies to CMH
do recognize cerebrosides from sclerotic cells, this is not suf-
ficient to enhance fungal attachment or macrophage killing
functions. We have recently demonstrated that the anti-CMH
antibody currently used interferes with ingestion and killing of
F. pedrosoi conidia by mouse macrophages (22). Therefore, a
positive control of antibody efficacy was achieved by replacing
sclerotic cells with conidia. Using these F. pedrosoi forms,
phagocytosis and microbial killing were enhanced after treat-
ment with antibodies to CMH (data not shown).
Analysis of CMH cellular distribution by immunofluores-
cence. The fact that antibodies to CMH were unable to kill
sclerotic bodies or to influence macrophage function was
somewhat surprising, since they recognize CMH from these
cells and produce such effects in several fungal models (4, 9,
21–24). We therefore evaluated the expression of surface
CMH in sclerotic cells as a function of melanin expression,
since we have previously demonstrated that F. pedrosoi aggre-
gates containing pigmented sclerotic forms react very poorly
with anticerebroside antibodies (22). After a slight centrifuga-
tion step, we were able to separate aggregated from disaggre-
gated cells and proceeded with indirect immunofluorescence.
Focusing our analysis on highly melanized cells, we found that
the edges of sclerotic bodies which enclose higher amounts of
pigment are not recognized by the antibody, while portions
with less melanin are more reactive (Fig. 7). Confirming prior
data, the surface of growing filaments is recognized in all of its
FIG. 5. Reactivity of F. pedrosoi cerebrosides with sera from human individuals (A) or with a monoclonal antibody to conserved CMH (B).
(A) Sera from patients with chromoblastomycosis (closed symbols, continuous lines) reacted similarly with CMH from sclerotic cells (triangles) or
mycelia (squares). Sera from healthy individuals (open symbols, dotted lines) reacted with cerebrosides with significantly lower intensities. (B) A
similar pattern of antibody reactivity was observed when cerebrosides from sclerotic cells (triangles) and mycelia (squares) were tested by ELISA
using a monoclonal antibody to conserved CMH. A higher level of affinity was observed when the mycelial cerebroside was used.
FIG. 6. Influence of a monoclonal antibody to CMH on the association of F. pedrosoi with macrophages (A) and on phagocyte antimicrobial
activity (B). The antibody to CMH did not influence the interaction between fungi and macrophages, since no significant differences in association
or killing (P  0.05) were observed when sclerotic cells were preincubated with irrelevant antibodies (control) or antibodies to cerebrosides
(anti-CMH). Student’s t test was used for statistical analysis. As a positive control of antibody efficacy, sclerotic cells were replaced with conidia.
Using these F. pedrosoi forms, phagocytosis and microbial killing were enhanced after treatment with antibodies to CMH (data not shown).
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extension, with some points where the reactivity is increased.
The relationship between melanin expression and CMH rec-
ognition was then investigated based on the property that,
while the F. pedrosoi melanin is alkali soluble (2), cerebrosides
and most of the cell wall glycans are not. Therefore, cell shape
and CMH expression are maintained in alkali-treated F.
pedrosoi.
After treatment of fungal cells with NaOH, pigmentation
was decreased, as determined visually in control or alkali-
treated cell pellets (Fig. 8A). Fungal preparations that were
not exposed to alkali treatment reacted clearly with antibodies
to melanin, but not with anti-CMH antibodies (Fig. 8B). Mel-
anin removal from different forms of F. pedrosoi was confirmed
by the decreased reaction of alkali-treated fungi with the pu-
rified preparation of antimelanin antibodies. These melanin-
depleted cells were strongly recognized by the monoclonal
antibody to CMH, confirming that the pigment masks recog-
nition of cerebrosides. Based on these results, we propose, in
the legend to Fig. 8C, an explanation for the resistance of
FIG. 7. Binding of antibodies to CMH to the cell surface of scle-
rotic cells is inhibited by pigmentation. Immunofluorescence analysis
using antibodies to CMH demonstrated that antibody reactivity is only
observed in cell wall regions in which melanin is poorly expressed. The
left panel shows microbial cells observed under differential interferen-
tial microscopy. The right panel shows the same cells observed under
fluorescence. Bar, 1.2 m.
FIG. 8. Influence of melanin shield on CMH recognition by a monoclonal antibody. (A) F. pedrosoi was treated with alkali (NaOH) or PBS
(control), followed by visual analysis of pigmentation. Alkali treatment resulted in fewer pigmented mycelia and sclerotic cells. (B) Untreated
mycelia (a) and conidia (a, inset) or sclerotic cells (g) reacted with the antibody to conserved cerebroside (anti-CMH) in limited regions of the cell
surface, as demonstrated in panels b and h, respectively. In contrast, these cells were efficiently recognized by the antibodies to melanin
(antimelanin, panels c and i). After alkali treatment, the cell shape of F. pedrosoi was maintained (d and j). In these cells, reactivity of fungal forms
with the antibody to CMH was greatly increased (e and k), which was accompanied by a clear decrease in the recognition of F. pedrosoi by
antibodies to melanin (f and l). Based on these results, we propose in panel C a hypothetical relationship between melanin expression and
anti-CMH reactivity in F. pedrosoi. Based on the clear inverse relationship between melanin (red fluorescence) and CMH (green fluorescence)
detection on the cell wall of F. pedrosoi (a), we hypothesize that young conidia and growing mycelia that express small quantities of melanin react
efficiently with antibodies to CMH, resulting in microbial killing through enhanced phagocytosis or direct antimicrobial action (b). A high amount
of melanin, commonly observed in sclerotic cells, would block sites for antibody binding, making fungi more resistant to the antimicrobial action
of macrophages and antibodies to CMH (c). Bars, 3.5 m (B; a, d, g and j), 1.5 m (insets), 1 m (C).
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sclerotic cells to the antimicrobial action of antibodies to
CMH.
DISCUSSION
Dimorphism is a crucial process used by some fungal species
to adapt to new environments and, in the case of pathogens, to
initiate the colonization process (19). Dimorphism includes
morphological transitions, and this differentiation step is usu-
ally associated with an intensive cell surface modification, in-
volving a finely regulated control of biosynthetic pathways. In
this context, F. pedrosoi and other chromoblastomycosis agents
are considered unique models for the study of fungal dimor-
phism, since all of them are able to grow in at least 4 different
morphological stages: (i) conidial, (ii) mycelial, (iii) pseudo-
hyphal, and (iv) sclerotic cells.
Recent studies have suggested the importance of CMH in
fungal development. For instance, Levery and coworkers dem-
onstrated that the inhibition of the enzyme ceramide glycosyl-
transferase, which catalyzes the final step in CMH synthesis,
affects spore germination, cell cycle, and hyphal growth (18) of
Aspergillus species. A series of studies from our group corrob-
orate with these data and strongly suggest that blocking fungal
CMH with anti-CMH antibodies can be an alternative for
treatment of mycoses (4, 9, 21–24), although the mechanism by
which it happens remains unclear. In our models, C. albicans,
C. neoformans, C. gloesporioides, and P. boydii had their growth
rate at least partially reduced by direct incubation with anti-
CMH antibodies (9, 23, 24). In F. pedrosoi, the incubation of
conidia with a monoclonal antibody to CMH promoted a sig-
nificant reduction in cell growth (22). However, immunofluo-
rescence data suggested that only newly formed conidia and
growing mycelia were reactive. Sclerotic cells, the prominent
forms in infected tissues, had presented a very weak pattern of
surface reactivity with these antibodies.
Structural modifications during F. pedrosoi differentiation
have been studied. Kneipp and coworkers described a higher
phosphatase activity in sclerotic cells than in conidial and my-
celial forms (16), which was associated with parasitism. How-
ever, it also suggests that these enzymes could be involved in F.
pedrosoi dimorphism, although the details by which it happens
remain to be elucidated. In addition, melanin expression is
more intensive in sclerotic cells than in conidia and mycelia of
F. pedrosoi (20). CMH structural diversity has been considered
to be linked with fungal dimorphism. For instance, the yeast-
mycelium transition in Histoplasma capsulatum and Sporothrix
schenckii was accompanied by fatty acid and sugar changes,
respectively (31, 32). Here we demonstrate a relationship be-
tween dimorphism and CMH structural changes in F. pedrosoi.
According to our results, sclerotic cells express a CMH never
reported before in the literature, consisting of a glucosyl
9-methyl-4,8 hydroxy-sphingadienine carrying an extra hy-
droxyl group positioned at C-4 or -5 of its long chain base.
Sclerotic cells also produce conserved cerebrosides, but in
lesser levels. In this regard, several attempts were done to
separate the two CMH species based on their polar properties;
however, none of them have succeeded (data not shown). The
lithiated molecular ion at m/z 750, considered in this work as a
marker of structural diversity, could be related to a previously
reported mammalian CMH (17), but data derived from
HPTLC and permethylation analyses confirmed the structure
proposed in Fig. 4. Also, the small amounts of this CMH
species at the surface of conidia support the postulate that
sclerotic cells found inside the host could arise directly from F.
pedrosoi spores (28).
Modifications in CMH ceramide structure can induce lipid
reorientation at the membrane level, resulting in variation at
side-by-side interactions (34). However, fungal CMH are de-
posited onto the cell wall (21, 23), and at this level, there is no
information about how ceramide hydroxylation could influence
the molecular wall architecture. Fatty acid length and hydroxy-
lation have been demonstrated to be relevant for GSL recog-
nition by antibodies (29, 34). Moreover, hydroxylation at long
chain base level can also modulate antibody binding (33).
Based on these findings, we evaluated the reactivity of cere-
brosides from mycelial or sclerotic bodies with sera from chro-
moblastomycosis patients and a monoclonal antibody pro-
duced against conserved CMH (9). Interestingly, we observed
that the cerebroside with an addition of an extra hydroxyl
group to its long chain base presented reactivity similar to that
of sera from infected individuals. A possible explanation for
this finding could be the fact that, in a chronic infection by F.
pedrosoi, patients are usually exposed to the different fungal
forms of this pathogen. Therefore, it is reasonable to expect
that antibodies to the different cerebrosides synthesized by F.
pedrosoi are produced in chromoblastomycosis, which supports
the result that polyclonal preparations similarly recognize dif-
ferent CMH. Another hypothesis is that, due to structural
similarities, antibodies to CMH could cross-react with different
cerebrosides from both mycelial and sclerotic cells. This hy-
pothesis was supported by the fact that a monoclonal antibody
produced against a conserved CMH (9) reacts similarly with
the mycelial CMH and the new cerebroside described in this
work, although a higher antibody affinity for the former was
observed. In this context, the additional hydroxyl group de-
tected in the cerebroside from sclerotic cells could represent a
physical barrier in the interaction between the antibody and
putative epitopes in CMH.
The fact that the monoclonal antibody to CMH recognizes
the different cerebrosides studied here was apparently in con-
flict with immunofluorescence assays, since antibody binding to
intact sclerotic cells was limited to specific cell wall regions.
During their growth in vitro, sclerotic bodies of F. pedrosoi
naturally form large cellular aggregates, which diminish the
access of antibodies to internally located cells (3). We there-
fore investigated the profile of reactivity of disaggregated cells
against anti-CMH antibodies. In contrast to what has been
demonstrated by our group using aggregates (22), the antibody
to CMH can interact with the cell surface of disaggregated
sclerotic bodies. However, our results clearly demonstrate that
the antibody recognition of CMH at the cell surface only oc-
curs in specific regions of the cell wall in which melanin, a dark
cell wall pigment produced by F. pedrosoi, is poorly expressed.
The fact that anti-CMH binding is inversely proportional to
melanin expression suggests that melanin could block the ac-
cess of external ligands to cell wall components, which may
have a relationship with the well-documented observation that
melanized fungi are much more resistant to antifungal agents
than nonpigmented cells (13). In fact, sclerotic bodies are
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susceptible to the antifungal action of antimelanin antibodies
(3) but not to that of antibodies to CMH.
To confirm the hypothesis that melanin masks cerebroside
recognition, we partially depleted F. pedrosoi forms of melanin
after overnight treatment with NaOH. Alkali-treated cells lost
their reactivity to antibodies to melanin but became efficiently
recognized by the anti-CMH antibody. The observation that
anti-CMH antibodies do not recognize sclerotic cells with the
same intensity as that observed to conidia and mycelia could
therefore be explained by the cell wall distribution of cerebro-
sides and melanin in F. pedrosoi, in which the pigment would
represent a thick cell wall layer protecting fungal cells against
different external agents. Also, the observation that melanin
impairs cerebroside detection in F. pedrosoi could also explain
the resistance of sclerotic bodies to the antimicrobial effects of
anti-CMH antibodies. We summarized this hypothesis in the
legend to Fig. 8C.
Our observations are in agreement with previous studies
showing that melanized fungi are more resistant to antifungal
drugs than nonpigmented cells (13). The use of small mole-
cules able to penetrate the melanin shield could be therefore a
relevant strategy for chromoblastomycosis defeat. In this re-
gard, it has been recently demonstrated that plant defensins
specifically recognize fungal CMH, resulting in microbial kill-
ing (30). Also, single-chain antibody fragments derived from
anti-CMH antibodies could also represent a feasible alterna-
tive to be used in the near future. Combined therapies could
also be an alternative, since drugs inhibiting melanin biosyn-
thesis could make sclerotic cells more susceptible to anti-CMH
antibodies.
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